Target intelligence / Profile preview

D-alanyl-D-alanine terminus of peptidoglycan cell wall precursors (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall component, Peptidoglycan precursor, Oligopeptide
01

Overview

The D-alanyl-D-alanine (D-Ala-D-Ala) terminus is a critical structural component of the peptidoglycan precursors in Gram-positive bacteria (Wikipedia, 2023). It serves as the substrate for transpeptidase enzymes, also known as penicillin-binding proteins, which catalyze the cross-linking of the bacterial cell wall to provide mechanical strength and osmotic protection (StatPearls, 2023). This dipeptide motif is the primary molecular target for glycopeptide antibiotics, such as vancomycin and teicoplanin (PubMed, 2000). By binding to the D-Ala-D-Ala terminus through a specific network of five hydrogen bonds, these drugs sterically inhibit both transglycosylation and transpeptidation, preventing the incorporation of precursors into the growing cell wall (Nature Reviews Microbiology, 2018). This inhibition leads to cell wall instability and subsequent bacterial lysis. Resistance to these drugs typically arises through the metabolic reprogramming of the cell wall synthesis pathway, replacing the terminal D-alanine with D-lactate or D-serine, which drastically reduces antibiotic binding affinity (NIH, 2021).

Other names
D-Ala-D-AlaD-alanyl-D-alaninePeptidoglycan precursor terminusUDP-N-acetylmuramyl-pentapeptide terminusD-alanyl-D-alanine dipeptide
02

Mechanism of action

Glycopeptide antibiotics bind to the D-Ala-D-Ala terminus of peptidoglycan precursors via a specific network of hydrogen bonds, sterically hindering the transglycosylation and transpeptidation steps of cell wall synthesis.

03

Biological functions

Cell wall biosynthesisPeptidoglycan cross-linkingBacterial structural integrityOsmotic protection
04

Disease associations

Bacterial infectionGram-positive bacterial infectionSepsis
05

Safety considerations

NephrotoxicityOtotoxicityRed Man Syndrome (infusion-related reaction)Development of glycopeptide-resistant enterococci (VRE)Vancomycin-resistant Staphylococcus aureus (VRSA)
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

VanA geneVanB geneMinimum Inhibitory Concentration (MIC)Bacterial culture and sensitivity

Beyond the preview

Go deeper on D-alanyl-D-alanine terminus of peptidoglycan cell wall precursors (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine terminus of peptidoglycan cell wall precursors (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call